TmCD19-IL18 CAR T cells

TmCD19-IL18 CAR T cells (also known as TMhuCART19-IL18 or huCART19-IL18) are an investigational, autologous, fourth-generation ("armored") chimeric antigen receptor (CAR) T-cell therapy. Developed by the University of Pennsylvania in collaboration with Tmunity Therapeutics (acquired by Kite Pharma), the therapy consists of a patient's own T cells genetically engineered to express a humanized CAR targeting the B-cell antigen CD19, while simultaneously secreting the pro-inflammatory cytokine interleukin-18 (IL-18). The co-expression of IL-18 is designed to enhance CAR T-cell expansion, persistence, and metabolic fitness, as well as to modulate the tumor microenvironment. TmCD19-IL18 CAR T cells are currently being evaluated in Phase I clinical trials for the treatment of relapsed or refractory CD19-positive B-cell malignancies, including non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL).

Other names

Anti-CD19 antigen/IL-18 expressing autologous CAR-T expressing IL-18 cell therapyCART19-IL18CART-19-IL18CART 19-IL18TmCD19-IL18TmCD-19-IL18TmCD 19-IL18TmCD19-IL18 CAR-T cellsTmCD-19-IL18 CAR-T cellsTmCD 19-IL18 CAR-T cellsanti-CD19 CAR-IL-18-expressing autologous T lymphocytesanti-CD-19 CAR-IL-18-expressing autologous T lymphocytesanti-CD 19 CAR-IL-18-expressing autologous T lymphocyteshuCART19-IL18huCART-19-IL18huCART 19-IL18huCART19-IL18 cellshuCART-19-IL18 cellshuCART 19-IL18 cells